# Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome

> **NCT06465823** · PHASE2 · RECRUITING · sponsor: **Stefano Vicari** · enrollment: 64 (estimated)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** Bumetanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06465823
- **Lead sponsor:** Stefano Vicari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-11
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465823, "Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06465823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*